M Jourdan

4.1k total citations · 1 hit paper
51 papers, 3.5k citations indexed

About

M Jourdan is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, M Jourdan has authored 51 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Hematology, 21 papers in Molecular Biology and 17 papers in Oncology. Recurrent topics in M Jourdan's work include Multiple Myeloma Research and Treatments (21 papers), Glycosylation and Glycoproteins Research (9 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). M Jourdan is often cited by papers focused on Multiple Myeloma Research and Treatments (21 papers), Glycosylation and Glycoproteins Research (9 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). M Jourdan collaborates with scholars based in France, United States and Germany. M Jourdan's co-authors include Bernard Klein, Régis Bataille, XG Zhang, Frédéric Houssiau, Marc Piechaczyk, L Aarden, J Brochier, John Wijdenes, Jean‐Pierre Liautard and John De Vos and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and The Journal of Experimental Medicine.

In The Last Decade

M Jourdan

48 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6

1989 650 citations Bernard Klein, XG Zhang et al. Blood profile →

Peers

Countries citing papers authored by M Jourdan

Since Specialization

Citations

This map shows the geographic impact of M Jourdan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M Jourdan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M Jourdan more than expected).

Fields of papers citing papers by M Jourdan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M Jourdan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M Jourdan. The network helps show where M Jourdan may publish in the future.

Co-authorship network of co-authors of M Jourdan

This figure shows the co-authorship network connecting the top 25 collaborators of M Jourdan. A scholar is included among the top collaborators of M Jourdan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M Jourdan. M Jourdan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Identification of a Positive Association between Mammary Adipose Cholesterol Content and Indicators of Breast Cancer Aggressiveness in a French Population 2020 ·Journal of Nutrition ·Caroline Goupille, Lobna Ouldamer, Michelle Pinault, (unknown), Flavie Arbion, M Jourdan, Philippe G. Frank	5
2	Skin Care Management For Medical And Aesthetic Procedures To Prevent Scarring 2019 ·SHILAP Revista de lepidopterología ·M Jourdan, (unknown), Émerson Silva Lima, Yanan Tian, Sophie Seité	1
3	Impact pronostique du délai d'induction de la radiothérapie adjuvante dans le cancer du sein 2019 ·Gynécologie Obstétrique Fertilité & Sénologie ·(unknown), (unknown), (unknown), (unknown), M Jourdan, Flavie Arbion, G. Body, Lobna Ouldamer	3
4	<p>Skin Care Management For Medical And Aesthetic Procedures To Prevent Scarring</p> 2019 ·Clinical Cosmetic and Investigational Dermatology ·M Jourdan, (unknown), Émerson Silva Lima, Yan Tian, Sophie Seité	23
5	Facteurs prédictifs de traitement conservateur après chimiothérapie néo-adjuvante dans le cancer du sein 2017 ·Gynécologie Obstétrique Fertilité & Sénologie ·(unknown), (unknown), (unknown), (unknown), M Jourdan, Flavie Arbion, G. Body, Lobna Ouldamer	0
6	Impact de la réponse histologique complète à la chimiothérapie néo-adjuvante pour cancer du sein selon le sous-type moléculaire 2017 ·Gynécologie Obstétrique Fertilité & Sénologie ·(unknown), G. Body, M Jourdan, (unknown), (unknown), (unknown), Flavie Arbion, Lobna Ouldamer	7
7	Febrile Ulceronecrotic Mucha-Habermann Disease: Treatment with Infliximab and Intravenous Immunoglobulins and Review of the Literature 2012 ·Dermatology ·(unknown), (unknown), (unknown), M Jourdan, A. Dadban, Corie Lok, G. Chaby	24
8	A Case Associating an Erosive Pustular Dermatosis of the Legs and Scalp 2012 ·Case Reports in Dermatology ·M Jourdan, G. Chaby, (unknown), Jean‐Philippe Arnault, Denis Chatelain, Catherine Lok	4
9	Efficient transduction of healthy and malignant plasma cells by lentiviral vectors pseudotyped with measles virus glycoproteins 2012 ·Leukemia ·Matthieu Schoenhals, Cecilia Frecha, Angélique Bruyer, Anouk Caraux, J.‐L. Veyrune, M Jourdan, Jérôme Moreaux, François–Loïc Cosset, Els Verhoeyen, Bernard Klein	10
10	A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines 2010 ·Haematologica ·Jérôme Moreaux, Bernard Klein, Régis Bataille, Géraldine Descamps, Sophie Maïga, Dirk Hose, (unknown), Anna Jauch, Thierry Rème, M Jourdan, Martine Amiot, Catherine Pellat‐Deceunynck	124
11	CDK1-cyclin B1 mediates the inhibition of proliferation induced by omega-3 fatty acids in MDA-MB-231 breast cancer cells 2005 ·The International Journal of Biochemistry & Cell Biology ·Aurélia Barascu, Pierre Besson, (unknown), Philippe Bougnoux, M Jourdan	68
12	Discriminating between the Activities of Human Neutrophil Elastase and Proteinase 3 Using Serpin-derived Fluorogenic Substrates 2002 ·Journal of Biological Chemistry ·Brice Korkmaz, Sylvie Attucci, E. Hazouard, Martine Ferrandière, M Jourdan, Michéle Brillard‐Bourdet, Luiz Juliano, Francis Gauthier	45
13	Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors 2000 ·Leukemia ·(unknown), John De Vos, Cosette Rebouissou, M Jourdan, (unknown), (unknown), John Wijdenes, Bernard Klein	54
14	Effect of an a-Linolenic Acid-Rich Diet on Rat Mammary Tumor Growth Depends on the Dietary Oxidative Status 2000 ·Nutrition and Cancer ·(unknown), M Jourdan, Emmanuelle Germain, (unknown), Éric Morel, Georges Durand, Philippe Bougnoux, Claude Lhuillery	55
15	Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1 2000 ·Cell Death and Differentiation ·M Jourdan, John De Vos, Nadir Mechti, Bernard Klein	115
16	Suppression of the promoter effect of polyunsaturated fatty acids by the absence of dietary vitamin E in experimental mammary carcinoma 1997 ·Cancer Letters ·Claude Lhuillery, (unknown), Emmanuelle Germain, M Jourdan, Philippe Bougnoux	18
17	Intrinsic B cell defects in NZB and NZW mice contribute to systemic lupus erythematosus in (NZB x NZW)F1 mice. 1996 ·The Journal of Experimental Medicine ·Luc Reininger, Thomas Winkler, Christian P. Kalberer, M Jourdan, Fritz Melchers, A Rolink	99
18	Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma 1994 ·Blood ·XG Zhang, (unknown), (unknown), ZY Lu, (unknown), M Jourdan, JM Boiron, Régis Bataille, Bernard Klein	26
19	Interleukin-6 is a Major Myeloma Cell Growth Factor In Vitro and In Vivo Especially in Patients with Terminal Disease 1990 ·Current topics in microbiology and immunology ·Bernard Klein, (unknown), M Jourdan, M Portier, Régis Bataille	29
20	Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. 1989 ·Journal of Clinical Investigation ·Régis Bataille, M Jourdan, (unknown), Bernard Klein	420

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact